Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202608003 Clinical Validation of the ArteVu Research Configuration for Cuff-less Blood Pressure Estimation using an Oscillometric Reference New Medical Device NA
N202608004 A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI INCLINE) New Drug Phase Ⅲ
N202608005 A Phase II Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of AR100DP1 in Subjects with Mild to Moderate Atopic Dermatitis New Drug Phase Ⅱ
N202608017 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of CRD-4730 In Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) New Drug Phase Ⅱ
N202608036 A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis New Drug Phase Ⅱ
N202608045 A randomized, open-label (unblinding), four-period, fully-replicated, crossover bioequivalence study to compare two edoxaban tosilate F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202608056 An Open-Label, Randomized, and Crossover Bioequivalence Study of Dapagliflozin 10 mg Film-Coated Tablet in Healthy Subjects under Fasting Conditions Bioavailability / Bioequivalence (BA/BE) NA
N202608057 A randomized, open-label (unblinding), crossover bioequivalence study to compare two empagliflozin F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202608058 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PYC-003, a Peptide-Phosphorodiamidate Morpholino Oligonucleotide Conjugate, in Healthy Adult Participants and Adult Participants with Confirmed PKD1 Mutation Associated Autosomal Dominant Polycystic Kidney Disease New Drug Phase Ⅰ
1 2 43 44 45 46 47 48 49 50 51 52 / 52

TOP